Antidotes for opioid overdose: a search for variations for their modification (literature review)
https://doi.org/10.24884/2078-5658-2024-21-6-107-115
Abstract
The unique physicochemical and pharmacological properties of synthetic drugs are responsible for both the morbidity and mortality associated with their overdose. Among the consequences resulting from misuse of these potent opioids, or in the case of mass casualties involving the large-scale use of weaponised synthetic opioids, is the need for higher and repeated doses of the competitive antagonist naloxone, currently the only drug available to reverse opioid overdose. We reviewed the reversal agents available worldwide, discuss the need for stronger, faster and longer-acting opioid antagonists to reverse opioid overdose, and look at possible areas of functionalization of morphinan-based opioid ligands.
About the Authors
O. A. Dravolina
Pavlov University
Russian Federation
Russian Federation
Dravolina Olga A., Cand. Sci. (Biol.), Head of the Laboratory of Experimental Pharmacology of Addiction, A. V. Valdman Institute of Pharmacology
6-8, Lev Tolstoy str., Saint Petersburg, 197022
+7 (812) 338-67-14
I. V. Belozertseva
Pavlov University
Russian Federation
Russian Federation
Belozertseva Irina V., Cand. Sci. (Biol.), Head of the Laboratory of Experimental Preclinical Studies with Vivarium, A. V. Valdman Institute of Pharmacology
6-8, Lev Tolstoy str., Saint Petersburg, 197022
+7 (812) 338-67-14
S. K. Moiseev
A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
Russian Federation
Russian Federation
Moiseev Sergey K., Dr. Sci. (Chem.), Head of the Laboratory of Fine Organic Synthesis
28, bld. 1, Vavilov str., Moscow, 119334
+7 (499) 135-92-02
References
1. Algera M. H., Kamp J., van der Schrier R. et al. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal // Br J Anaesth. – 2019. – Vol. 122, № 6. – e168–e179. https://doi.org/10.1016/j.bja.2018.12.023.
2. Bentley K. W., Boura A. L., Fitzgerald A. E. et al. Compounds possessing morphine-antagonizing or powerful analgesic properties // Nature. – 1965. – Vol. 206. – P. 102–103. https://doi.org/10.1038/206102a0.
3. Bird H. E., Huhn A. S., Dunn K. E. Fentanyl absorption, distribution, metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl // J Addict Med. – 2023. – Vol. 17, № 5. – P. 503–508. https://doi.org/10.1097/ADM.0000000000001185.
4. Blane G. F., Boura A. L., Fitzgerald A. E. et al. Actions of etorphinehydrochloride, (M99): a potent morphine-like agent // Br J Pharmacol Chemother. – 1967. – Vol. 30. – P. 11–22. https://doi.org/10.1111/j.1476-5381.1967.tb02108.x.
5. Boyer E. W. Management of opioid analgesic overdose // N Engl J Med. – 2012. – Vol. 367, № 2. – P. 146–155. https://doi.org/10.1056/NEJMra1202561.
6. Broadbear J. H., Sumpter T. L., Burke T. F. et al. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine // J Pharmacol Exp Ther. – 2000. – Vol. 294, № 3. – P. 933–940.
7. Crabtree B. L. Review of naltrexone, a long-acting opiate antagonist // Clin Pharm. – 1984. – Vol. 3, № 3. – P. 273–280.
8. Crystal R., Ellison M., Purdon C. et al. Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose // Clin Pharmacol Drug Dev. – 2024. – Vol. 13, № 1. – P. 58–69. https://doi.org/10.1002/cpdd.1312.
9. Cueva J. P., Roche C., Ostovar M. et al. C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors // J Med Chem. – 2015. – Vol. 58, № 10. – P. 4242–4249. https://doi.org/10.1021/acs.jmedchem.5b00130.
10. Edinoff A. N., Nix C. A., Reed T. D. et al. Pharmacologic and clinical considerations of nalmefene, a long duration opioid antagonist, in opioid overdose // Psychiatry Int. – 2021. – Vol. 2, № 4. – P. 365–378. https://doi.org/10.3390/psychiatryint2040028.
11. Fairbairn N., Coffin P. O., Walley A. Y. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic // Int J Drug Policy. – 2017. – Vol. 46. – P. 172–179. https://doi.org/10.1016/j.drugpo.2017.06.005.
12. France C. P., Ahern G. P., Averick S. et al. Countermeasures for preventing and treating opioid overdose // Clin Pharmacol Ther. – 2021. – Vol. 109, № 3. – P. 578–590. https://doi.org/10.1002/cpt.2098.
13. Gillis E. P., Eastman K. J., Hill M. D. et al. Application of fluorine in medicinal chemistry // J Med Chem. – 2015. – Vol. 58, № 21. – P. 8315–8359. https://doi.org/10.1021/acs.jmedchem.5b00258.
14. Harper M. H., Hickey R. F., Cromwell T. H. et al. The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man // J Pharmacol Exp Ther. – 1976. – Vol. 199, № 2. – P. 464–468.
15. Harris K., Page C. B., Samantray S. et al. One single large intramuscular dose of naloxone is effective and safe in suspected heroin poisoning // Emerg Med Austral. – 2020. – Vol. 32, № 1. – P. 88–92. https://doi.org/10.1111/1742-6723.13344.
16. Hart E. R., McCauley E. L. The pharmacology of N-allylnormorphine as compared with morphine // J Pharmacol Exp Ther. – 1944. – Vol. 82. – P. 339–348.
17. Hill L. G., Zagorski C. M., Loera L. J. Increasingly powerful opioid antagonists are not necessary // Int J Drug Policy. – 2022. – Vol. 99. – P. 103457. https://doi.org/10.1016/j.drugpo.2021.103457.
18. Hill R., Santhakumar R., Dewey W. et al. Fentanyl depression of respiration: comparison with heroin and morphine // Br J Pharmacol. – 2020. – Vol. 177, № 2. – P. 254–265. https://doi.org/10.1111/bph.14860.
19. Husbands S. M., Lewis J. W. Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse // Mini Rev Med Chem. – 2003. – Vol. 3, № 2. – P. 137–144. https://doi.org/10.2174/1389557033405395.
20. Infante A. F., Elmes A. T., Gimbar R. P. et al. Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement // Int J Drug Policy. – 2024. – Vol. 124. – P. 104323. https://doi.org/10.1016/j.drugpo.2024.104323.
21. Jimenez V. M. Jr., Castaneda G., France C. P. Methocinnamox reverses and prevents fentanyl-induced ventilatory depression in rats // J Pharmacol Exp Ther. – 2021. – Vol. 377, № 1. – P. 29–38. https://doi.org/10.1124/jpet.120.000387.
22. Jordan C. G., Kennalley A. L., Roberts A. L. et al. The potential of methocinnamox as a future treatment for opioid use disorder: a narrative review // Pharmacy (Basel). – 2022. – Vol. 10, № 3. – P. 48. https://doi.org/10.3390/pharmacy10030048.
23. Kiyatkin E. A. Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl // Neuropharmacology. – 2019. – Vol. 151. – P. 219–226. https://doi.org/10.1016/j.neuropharm.2019.02.008.
24. Lewis J., Smith C., McCarthy P. et al. New 14-aminomorphinones and codeinones // NIDA Research Monograph. – 1988. – Vol. 90. – P. 136–143.
25. Lombardi J., Villeneuve E., Gosselin S. In response to: “the evolution of recommended naloxone dosing for opioid overdose by medical specialty” // J Med Toxicol. – 2016. – Vol. 12, № 4. – P. 412–413. https://doi.org/10.1007/s13181-016-0591-3.
26. Maguire D. R., France C. P. Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder // J Exp Anal Behav. – 2023. – Vol. 119, № 2. – P. 392–406. https://doi.org/10.1002/jeab.831.
27. Mann J., Samieegohar M., Chaturbedi A. et al. Development of a translational model to assess the impact of opioid overdose and naloxone dosing on respiratory depression and cardiac arrest // Clin Pharmacol Ther. – 2022. – Vol. 112, № 5. – P. 1020–1032. https://doi.org/10.1002/cpt.2696.
28. Miller M. W., Wild M. A., Lance W. R. Efficacy and safety of naltrexone hydrochloride for antagonizing carfentanil citrate immobilization in captive Rocky Mountain elk (Cervus elaphus nelsoni) // J Wildl Dis. – 1996. – Vol. 32, № 2. – P. 234–239.
29. Nieland N. P., Moynihan H. A., Carrington S. et al. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones // J Med Chem. – 2006. – Vol. 49, № 17. – P. 5333–5338. https://doi.org/10.1021/jm0604777.
30. Purser S., Moore P. R., Swallow S. et al. Fluorine in medicinal chemistry // Chem Soc Rev. – 2008. – Vol. 32, № 16. – P. 320–330. https://doi.org/10.1039/b610213c.
31. Sandulenko I. V., Ambartsumyan A. A., Moiseev S. K. Fluorinated and [18F] fluorinated morphinan based opioid ligands // Org Biomol Chem. – 2020. – Vol. 18, № 29. – P. 5533–5557. https://doi.org/10.1039/d0ob00619j.
32. Sandulenko I. V., Belozertseva I. V., Zvartau E. E. et al. C(21)-fluorinated thevinol scaffold for opioid ligands. 21,21,21-Trifluoro-6-O-nororvino ls: Design, synthesis and analgesic activity // Eur J Med Chem. – 2023. – Vol. 252. – P. 115296. https://doi.org/10.1016/j.ejmech.2023.115296.
33. Sandulenko I. V., Kovaleva E. S., Peregudov A. S. et al. 21,21,21-Trifluorothevinone: the straightest way to fluorinated thevinols and orvinols // ChemistrySelect. – 2016. – Vol. 1, № 5. – P. 1004–1005. https://doi.org/10.1002/slct.201600233.
34. Sandulenko I. V., Kovaleva E. S., Zelentsova M. V. et al. Control of the diastereoselectivity at C(20) in the formation of C(21)-fluorinated thevinols // Org Biomol Chem. – 2023. – Vol. 21, № 7. – P. 1440–1449. https://doi.org/10.1039/D2OB02144G.
35. Sirohi S., Dighe S. V., Madia P. A. et al. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity // J Pharmacol Exp Ther. – 2009. – Vol. 330, № 2. – P. 513–519. https://doi.org/10.1124/jpet.109.152678.
36. Skolnick P. Treatment of overdose in the synthetic opioid era // Pharmacol Ther. – 2022. – Vol. 233. – P. 108019. https://doi.org/10.1016/j.pharmthera.2021.108019.
37. Skolnick P., Paavola J., Heidbreder C. Synthetic opioids have disrupted conventional wisdom for treating opioid overdose // Drug Alcohol Depend Rep. – 2024. – Vol. 12. – P. 1100268. https://doi.org/10.1016/j.dadr.2024.100268.
38. Sladojevich F., Arlow S. I., Tang P. et al. Late-stage deoxyfluorination of alcohols with PhenoFluor // J Am Chem Soc. – 2013. – Vol. 135, № 7. – P. 2470–2473. https://doi.org/10.1021/ja3125405.
39. Somerville N. J., O’Donnell J., Gladden R. M. et al. Characteristics of fentanyl overdose – Massachusetts, 2014-2016 // MMWR Mor Mortal Wkly Rep. – 2017. – Vol. 166, № 14. – P. 382–386. https://doi.org/10.15585/mmwr.mm6614a2.
40. Sorrentino J. P., Altman R. A. Fluoroalkylation of dextromethorphan improves cns exposure and metabolic stability // ACS Med Chem Lett. – 2022. – Vol. 13, № 4. – P. 707–713. https://doi.org/10.1021/acsmedchemlett.2c00055.
41. Sorrentino J. P., Ambler B. R., Altman R. A. Late-stage conversion of a metabolically labile aryl methyl ether-containing natural product to fluoroalkyl analogues // J Org Chem. – 2020. – Vol. 85, № 8. – P. 5416–5427. https://doi.org/10.1021/acs.joc.0c00125.
42. Strauss D. G., Li Z., Chaturbedi A. et al. Intranasal naloxone repeat dosing strategies and fentanyl overdose: a simulation-based randomized clinical trial // JAMA Netw Open. – 2024. – Vol. 7, № 1. – P. e2351839. https://doi.org/10.1001/jamanetworkopen.2023.51839.
43. Strickland J. C., Marks K. R., Smith K. E. et al. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose // Int J Drug Policy. – 2022. – Vol. 106. – P. 103751. https://doi.org/10.1016/j.drugpo.2022.103751.
44. Takemori A. E., Hayashi G., Smits S. E. Studies on the quantitative antagonism of analgesics by naloxone and diprenorphine // Eur J Pharmacol. – 1972. – Vol. 20. – P. 85–92. https://doi.org/10.1016/0014-2999(72)90219-1.
45. Todaro D. R., Volkow N. D., Langleben D. D. et al. Collateral damage: neurological correlations of non-fatal overdose in the era of fentanyl-xylazine // Neurosci Insights. – 2024. – Vol. 19. – P. 1–4. https://doi.org/10.1177/26331055241247156.
46. Trøstheim M., Eikemo M., Haaker J. et al. Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade // Neuropsychopharmacology. – 2023. – Vol. 48, № 2. – P. 299–307. https://doi.org/10.1038/s41386-022-01416-z.
47. Unna K. Antagonistic effect of N-allylnormorphine upon morphine // J Pharmacol Exp Ther. – 1943. – Vol. 79. – P. 2–31.
48. Volkow N., Collins F. The role of science in addressing the opioid crisis // N Engl J Med. – 2017. – Vol. 377, № 4. – P. 391–394. https://doi.org/10.1056/NEJMsr1706626.
49. Wang D. S., Sternbach G., Varon J. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine // J Emerg Med. – 1998. – Vol. 16, № 3. – P. 471–475. https://doi.org/10.1016/s0736-4679(98)00019-5.
50. Watson W. A., Steele M. T., Muelleman R. L. et al. Opioid toxicity recurrence after an initial response to naloxone // J Toxicol Clin Toxicol. – 1998. – Vol. 36, № 1–2. – P. 11–17. https://doi.org/10.3109/15563659809162577.
51. Winstanley E. L., Mahoney J. J. 3rd, Castillo F. et al. Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: a systematic review // Drug Alcohol Depend. – 2021. – Vol. 226. – P. 108838. https://doi.org/10.1016/j.drugalcdep.2021.108838.
52. Zamora J. C., Smith H. R., Jennings E. M. et al. Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox // Pharmacol Res Perspect. – 2021. – Vol. 9, № 6. – P. e00887. https://doi.org/10.1002/prp2.887.
53. Zelentsova M. V., Sandulenko I. V., Ambartsumyan A.A. et al. C(21)-Diand monofluorinated scaffold for thevinol/orvinol-based opioid receptor ligands // Org Biomol Chem. – 2023. – Vol. 21, № 45. – P. 9091–9100. https://doi.org/10.1039/D3OB01577G.
54. Zhou Y., Wang J., Gu Z. et al. Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II–III clinical trials of major pharmaceutical companies: new structural trends and therapeutic areas // Chem Rev. – 2016. – Vol. 116, № 2. – P. 422–518. https://doi.org/10.1021/acs.chemrev.5b00392.
Review
For citations:
Dravolina O.A., Belozertseva I.V., Moiseev S.K. Antidotes for opioid overdose: a search for variations for their modification (literature review). Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2024;21(6):107-115. (In Russ.) https://doi.org/10.24884/2078-5658-2024-21-6-107-115
Email this article 